AxoGen (NASDAQ:AXGN) Upgraded to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of AxoGen (NASDAQ:AXGN) from a hold rating to a strong-buy rating in a report published on Saturday,Wall Street Zen reports.

A number of other brokerages have also issued reports on AXGN. HC Wainwright boosted their target price on shares of AxoGen from $53.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday. Truist Financial increased their price target on shares of AxoGen from $53.00 to $60.00 and gave the company a “buy” rating in a report on Thursday. Canaccord Genuity Group increased their price target on shares of AxoGen from $55.00 to $60.00 and gave the company a “buy” rating in a report on Thursday. Leerink Partners raised their price target on shares of AxoGen from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Morgan Stanley downgraded shares of AxoGen to a “hold” rating in a report on Tuesday, September 29th. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $57.92.

AxoGen Trading Down 0.5%

AxoGen stock opened at $49.37 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 5.04 and a current ratio of 12.02. The business’s 50-day simple moving average is $42.86 and its 200-day simple moving average is $39.45. The firm has a market capitalization of $2.95 billion, a PE ratio of -75.95 and a beta of 1.17. AxoGen has a 52 week low of $21.68 and a 52 week high of $52.91.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.08. AxoGen had a negative return on equity of 5.35% and a negative net margin of 11.96%. The business had revenue of $75.83 million during the quarter, compared to analysts’ expectations of $73.45 million. Equities research analysts forecast that AxoGen will post -0.44 earnings per share for the current year.

Insider Transactions at AxoGen

In other AxoGen news, EVP Marc Began sold 67,500 shares of AxoGen stock in a transaction on Monday, August 10th. The shares were sold at an average price of $47.34, for a total transaction of $3,195,450.00. Following the sale, the executive vice president owned 50,135 shares in the company, valued at $2,373,390.90. The trade was a 57.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Wendell sold 13,353 shares of AxoGen stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $48.42, for a total transaction of $646,552.26. Following the sale, the director owned 107,976 shares in the company, valued at $5,228,197.92. This represents a 11.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 98,503 shares of company stock valued at $4,656,947 in the last ninety days. 2.44% of the stock is owned by company insiders.

Hedge Funds Weigh In On AxoGen

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in shares of AxoGen by 46.0% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 30,150 shares of the medical equipment provider’s stock worth $1,264,000 after buying an additional 9,500 shares during the period. Sterling Capital Management LLC boosted its stake in AxoGen by 858.9% in the 3rd quarter. Sterling Capital Management LLC now owns 1,774 shares of the medical equipment provider’s stock valued at $74,000 after buying an additional 1,589 shares in the last quarter. State of Alaska Department of Revenue grew its position in AxoGen by 16.9% in the third quarter. State of Alaska Department of Revenue now owns 2,833 shares of the medical equipment provider’s stock valued at $118,000 after acquiring an additional 409 shares during the period. Artemis Investment Management LLP grew its position in AxoGen by 27.5% in the third quarter. Artemis Investment Management LLP now owns 1,780,992 shares of the medical equipment provider’s stock valued at $74,659,000 after acquiring an additional 384,200 shares during the period. Finally, Sequoia Financial Advisors LLC bought a new stake in AxoGen in the second quarter valued at $272,000. 80.29% of the stock is owned by institutional investors.

AxoGen News Roundup

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Strong Q3 execution and higher guidance: AxoGen reported 26% revenue growth and 45% adjusted EBITDA growth for the third quarter of 2026. Management maintained a target of at least $290 million in 2026 sales and expects gross margin of 73% or higher, reinforcing the company’s growth and operating-leverage story. AxoGen Third-Quarter Earnings Results
• Positive Sentiment: Analysts raised their targets: Canaccord Genuity increased its price target to $60 from $55 and maintained a Buy rating. Truist also raised its target to $60 from $53, while Wells Fargo increased its target to $56 from $48 and kept an Overweight rating. HC Wainwright lifted its target to $56 from $53 and retained a Buy rating. These revisions indicate improving confidence in AxoGen’s earnings outlook. Truist AxoGen Price Target Update
• Positive Sentiment: BioCircuit acquisition expands the opportunity: An investment analysis characterized AxoGen as evolving toward a leading procedural platform in peripheral nerve repair. The planned $200 million BioCircuit, or NerveTape, acquisition is intended to reduce technical barriers for surgeons, broaden the addressable market and be accretive at an estimated 5.9 times 2027 sales. AxoGen Taking the Friction Out of Nerve Repair
• Neutral Sentiment: Valuation remains an investor debate: Coverage is focused on whether AXGN’s growth prospects justify its elevated valuation after its substantial advance. The stock’s performance relative to other medical companies may attract momentum investors, but also raises the risk that much of the near-term optimism is already reflected in the share price. Does AxoGen Have More Upside?
• Negative Sentiment: Profitability and execution risks remain: Despite improving adjusted EBITDA, AxoGen continues to report negative net income and analysts expect a full-year loss. Investors must also weigh acquisition integration, dilution and the company’s premium valuation against the possibility of slower growth.

AxoGen Company Profile

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.